T1	B-Protein	0	11	Interleukin	Interleukin	B-NP	NN	B-protein	3	NMOD	B-protein
T1	I-Protein	11	12	-	-	O	HYPH	I-protein	1	P	I-protein
T1	I-Protein	12	14	10	10	B-NP	CD	I-protein	4	SUB	I-protein
O	O	15	25	stabilizes	stabilize	B-VP	VBZ	O	0	ROOT	O
T2	B-Protein	26	36	inhibitory	inhibitory	B-NP	JJ	B-protein	6	NMOD	B-protein
T2	I-Protein	37	43	kappaB	kappaB	I-NP	NN	I-protein	8	NMOD	I-protein
T2	I-Protein	43	44	-	-	B-NP	HYPH	O	8	NMOD	O
T2	I-Protein	44	49	alpha	alpha	I-NP	NN	O	4	OBJ	O
O	O	50	52	in	in	B-PP	IN	O	8	NMOD	O
O	O	53	58	human	human	B-NP	JJ	B-cell_type	11	NMOD	B-cell_type
O	O	59	68	monocytes	monocyte	I-NP	NNS	I-cell_type	9	PMOD	I-cell_type
O	O	68	69	.	.	O	.	O	4	P	O

T3	B-Protein	71	82	Interleukin	Interleukin	B-NP	NN	B-protein	9	SUB	B-protein
T3	I-Protein	82	83	-	-	O	HYPH	O	1	P	O
T3	I-Protein	83	85	10	10	B-NP	CD	O	1	NMOD	O
O	O	86	87	(	(	O	(	O	8	DEP	O
T4	B-Protein	87	89	IL	IL	B-NP	NN	B-protein	6	NMOD	B-protein
T4	I-Protein	89	90	-	-	B-NP	HYPH	I-protein	8	DEP	I-protein
T4	I-Protein	90	92	10	10	I-NP	CD	I-protein	6	NMOD	I-protein
O	O	92	93	)	)	O	)	O	1	NMOD	O
O	O	94	102	protects	protect	B-VP	VBZ	O	0	ROOT	O
O	O	103	110	animals	animal	B-NP	NNS	O	9	OBJ	O
O	O	111	115	from	from	B-PP	IN	O	9	VMOD	O
O	O	116	122	lethal	lethal	B-NP	JJ	O	13	NMOD	O
O	O	123	134	endotoxemia	endotoxemia	I-NP	NN	O	11	PMOD	O
O	O	134	135	.	.	O	.	O	9	P	O

O	O	136	140	This	This	B-NP	DT	O	3	NMOD	O
O	O	141	151	beneficial	beneficial	I-NP	JJ	O	3	NMOD	O
O	O	152	158	effect	effect	I-NP	NN	O	4	SUB	O
O	O	159	161	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	162	170	mediated	mediate	I-VP	VBN	O	4	VC	O
O	O	170	171	,	,	O	,	O	5	P	O
O	O	172	174	in	in	B-PP	IN	O	5	VMOD	O
O	O	175	179	part	part	B-NP	NN	O	7	PMOD	O
O	O	179	180	,	,	O	,	O	5	P	O
O	O	181	183	by	by	B-PP	IN	O	5	VMOD	O
O	O	184	194	inhibition	inhibition	B-NP	NN	O	10	PMOD	O
O	O	195	197	of	of	B-PP	IN	O	11	NMOD	O
O	O	198	210	inflammatory	inflammatory	B-NP	JJ	B-protein	15	NMOD	B-protein
O	O	211	219	cytokine	cytokine	I-NP	NN	I-protein	15	NMOD	I-protein
O	O	220	230	production	production	I-NP	NN	O	12	PMOD	O
O	O	230	231	,	,	O	,	O	11	P	O
O	O	232	241	including	include	B-PP	VBG	O	11	NMOD	O
T5	B-Protein	242	247	tumor	tumor	B-NP	NN	B-protein	22	NMOD	B-protein
T5	I-Protein	248	256	necrosis	necrosis	I-NP	NN	I-protein	22	NMOD	I-protein
T5	I-Protein	257	263	factor	factor	I-NP	NN	I-protein	22	NMOD	I-protein
T5	I-Protein	263	264	-	-	O	HYPH	I-protein	22	P	I-protein
T5	I-Protein	264	269	alpha	alpha	B-NP	SYM	I-protein	17	PMOD	I-protein
O	O	270	271	(	(	O	(	O	27	DEP	O
T6	B-Protein	271	274	TNF	TNF	B-NP	NN	B-protein	26	NMOD	B-protein
T6	I-Protein	274	275	-	-	O	HYPH	I-protein	26	P	I-protein
T6	I-Protein	275	280	alpha	alpha	B-NP	SYM	I-protein	27	DEP	I-protein
O	O	280	281	)	)	O	)	O	22	NMOD	O
O	O	281	282	.	.	O	.	O	4	P	O

O	O	283	291	Evidence	Evidence	B-NP	NN	O	2	SUB	O
O	O	292	300	suggests	suggest	B-VP	VBZ	O	0	ROOT	O
O	O	301	305	that	that	B-SBAR	IN	O	2	VMOD	O
T7	B-Protein	306	308	IL	IL	B-NP	NN	B-protein	5	NMOD	B-protein
T7	I-Protein	308	309	-	-	B-NP	HYPH	I-protein	7	SUB	I-protein
T7	I-Protein	309	311	10	10	I-NP	CD	I-protein	5	NMOD	I-protein
O	O	312	315	may	may	B-VP	MD	O	3	SBAR	O
O	O	316	323	inhibit	inhibit	I-VP	VB	O	7	VC	O
O	O	324	334	activation	activation	B-NP	NN	O	8	OBJ	O
O	O	335	337	of	of	B-PP	IN	O	9	NMOD	O
O	O	338	341	the	the	B-NP	DT	O	15	NMOD	O
O	O	342	355	transcription	transcription	I-NP	NN	B-protein	15	NMOD	B-protein
O	O	356	362	factor	factor	I-NP	NN	I-protein	15	NMOD	I-protein
T28	B-Entity	363	370	nuclear	nuclear	B-NP	JJ	I-protein	15	NMOD	I-protein
T28	I-Entity	371	377	factor	factor	I-NP	NN	I-protein	17	NMOD	I-protein
T28	I-Entity	377	378	-	-	O	HYPH	O	17	P	O
T28	I-Entity	378	384	kappaB	kappaB	B-NP	NN	B-protein	10	PMOD	B-protein
O	O	385	386	(	(	O	(	O	22	DEP	O
T29	B-Entity	386	388	NF	NF	B-NP	NN	B-protein	21	NMOD	B-protein
T29	I-Entity	388	389	-	-	B-NP	HYPH	I-protein	21	NMOD	I-protein
T29	I-Entity	389	395	kappaB	kappaB	I-NP	NN	I-protein	22	DEP	I-protein
O	O	395	396	)	)	O	)	O	17	NMOD	O
O	O	397	404	through	through	B-PP	IN	O	8	VMOD	O
O	O	405	407	an	an	B-NP	DT	O	26	NMOD	O
O	O	408	415	unknown	unknown	I-NP	JJ	O	26	NMOD	O
O	O	416	425	mechanism	mechanism	I-NP	NN	O	23	PMOD	O
O	O	425	426	.	.	O	.	O	2	P	O

T30	B-Entity	427	429	NF	NF	B-NP	NN	B-protein	3	NMOD	B-protein
T30	I-Entity	429	430	-	-	I-NP	HYPH	I-protein	3	NMOD	I-protein
T30	I-Entity	430	436	kappaB	kappaB	I-NP	NN	I-protein	4	NMOD	I-protein
O	O	437	447	activation	activation	I-NP	NN	O	10	SUB	O
O	O	448	450	in	in	B-PP	IN	O	4	NMOD	O
O	O	451	459	response	response	I-PP	NN	O	5	PMOD	O
O	O	460	462	to	to	I-PP	TO	O	6	NMOD	O
O	O	463	475	inflammatory	inflammatory	B-NP	JJ	O	9	NMOD	O
O	O	476	483	signals	signal	I-NP	NNS	O	7	PMOD	O
O	O	484	486	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	487	496	dependent	dependent	B-ADJP	JJ	O	10	PRD	O
O	O	497	501	upon	upon	B-PP	IN	O	11	AMOD	O
O	O	502	513	degradation	degradation	B-NP	NN	O	23	NMOD	O
O	O	514	516	of	of	B-PP	IN	O	13	NMOD	O
O	O	517	520	its	its	B-NP	PRP$	O	18	NMOD	O
O	O	521	531	associated	associate	I-NP	VBN	O	18	NMOD	O
T31	B-Entity	532	542	inhibitory	inhibitory	I-NP	JJ	O	18	NMOD	O
T31	I-Entity	543	550	peptide	peptide	I-NP	NN	O	21	NMOD	O
O	O	550	551	,	,	O	,	O	21	P	O
T8	B-Protein	552	562	inhibitory	inhibitory	B-NP	JJ	B-protein	21	NMOD	B-protein
T8	I-Protein	563	569	kappaB	kappaB	I-NP	NN	I-protein	14	PMOD	I-protein
T8	I-Protein	569	570	-	-	O	HYPH	O	23	P	O
T8	I-Protein	570	575	alpha	alpha	O	SYM	O	12	PMOD	O
O	O	576	577	(	(	O	(	O	28	DEP	O
T9	B-Protein	577	584	IkappaB	IkappaB	B-NP	NN	B-protein	27	NMOD	B-protein
T9	I-Protein	584	585	-	-	O	HYPH	O	27	P	O
T9	I-Protein	585	590	alpha	alpha	B-NP	SYM	O	28	DEP	O
O	O	590	591	)	)	O	)	O	23	NMOD	O
O	O	591	592	.	.	O	.	O	10	P	O

O	O	593	595	We	We	B-NP	PRP	O	2	SUB	O
O	O	596	608	hypothesized	hypothesize	B-VP	VBD	O	0	ROOT	O
O	O	609	613	that	that	B-SBAR	IN	O	2	VMOD	O
T10	B-Protein	614	616	IL	IL	B-NP	NN	B-protein	5	NMOD	B-protein
T10	I-Protein	616	617	-	-	B-NP	HYPH	I-protein	7	SUB	I-protein
T10	I-Protein	617	619	10	10	B-NP	CD	I-protein	5	NMOD	I-protein
O	O	620	628	prevents	prevent	B-VP	VBZ	O	3	SBAR	O
O	O	629	634	human	human	B-NP	JJ	O	13	NMOD	O
O	O	635	643	monocyte	monocyte	I-NP	NN	O	12	NMOD	O
T32	B-Entity	644	646	NF	NF	I-NP	NN	B-protein	12	NMOD	B-protein
T32	I-Entity	646	647	-	-	B-NP	HYPH	I-protein	12	NMOD	I-protein
T32	I-Entity	647	653	kappaB	kappaB	I-NP	NN	I-protein	13	NMOD	I-protein
O	O	654	664	activation	activation	I-NP	NN	O	19	NMOD	O
O	O	665	668	and	and	O	CC	O	19	NMOD	O
O	O	669	678	resultant	resultant	B-NP	JJ	O	19	NMOD	O
T11	B-Protein	679	682	TNF	TNF	I-NP	NN	B-protein	19	NMOD	B-protein
T11	I-Protein	682	683	-	-	O	HYPH	O	19	P	O
T11	I-Protein	683	688	alpha	alpha	O	SYM	O	19	NMOD	O
O	O	689	699	production	production	B-NP	NN	O	7	OBJ	O
O	O	700	702	by	by	B-PP	IN	O	19	NMOD	O
O	O	703	716	stabilization	stabilization	B-NP	NN	O	20	PMOD	O
O	O	717	719	of	of	B-PP	IN	O	21	NMOD	O
T12	B-Protein	720	727	IkappaB	IkappaB	B-NP	NN	B-protein	25	NMOD	B-protein
T12	I-Protein	727	728	-	-	O	HYPH	O	25	P	O
T12	I-Protein	728	733	alpha	alpha	B-NP	SYM	O	22	PMOD	O
O	O	733	734	.	.	O	.	O	2	P	O

O	O	735	738	The	The	B-NP	DT	O	2	NMOD	O
O	O	739	746	purpose	purpose	I-NP	NN	O	6	SUB	O
O	O	747	749	of	of	B-PP	IN	O	2	NMOD	O
O	O	750	754	this	this	B-NP	DT	O	5	NMOD	O
O	O	755	760	study	study	I-NP	NN	O	3	PMOD	O
O	O	761	764	was	be	B-VP	VBD	O	0	ROOT	O
O	O	765	767	to	to	B-VP	TO	O	8	VMOD	O
O	O	768	777	determine	determine	I-VP	VB	O	6	PRD	O
O	O	778	781	the	the	B-NP	DT	O	10	NMOD	O
O	O	782	788	effect	effect	I-NP	NN	O	8	OBJ	O
O	O	789	791	of	of	B-PP	IN	O	10	NMOD	O
T13	B-Protein	792	794	IL	IL	B-NP	NN	B-protein	13	NMOD	B-protein
T13	I-Protein	794	795	-	-	B-NP	HYPH	I-protein	11	PMOD	I-protein
T13	I-Protein	795	797	10	10	B-NP	CD	I-protein	13	NMOD	I-protein
O	O	798	800	on	on	B-PP	IN	O	10	NMOD	O
O	O	801	819	lipopolysaccharide	lipopolysaccharide	B-NP	NN	O	38	NMOD	O
O	O	820	821	(	(	O	(	O	19	DEP	O
O	O	821	824	LPS	LPS	B-NP	NN	O	19	DEP	O
O	O	824	825	)	)	O	)	O	16	NMOD	O
O	O	825	826	-	-	O	HYPH	O	16	P	O
O	O	826	833	induced	induce	B-NP	VBN	O	38	NMOD	O
O	O	834	839	human	human	I-NP	JJ	O	24	NMOD	O
O	O	840	848	monocyte	monocyte	I-NP	NN	O	24	NMOD	O
T14	B-Protein	849	852	TNF	TNF	I-NP	NN	B-protein	27	NMOD	B-protein
T14	I-Protein	852	853	-	-	O	HYPH	O	27	NMOD	O
T14	I-Protein	853	858	alpha	alpha	O	SYM	O	27	NMOD	O
O	O	859	869	production	production	B-NP	NN	O	38	NMOD	O
O	O	869	870	,	,	O	,	O	38	P	O
T33	B-Entity	871	873	NF	NF	B-NP	NN	B-protein	31	NMOD	B-protein
T33	I-Entity	873	874	-	-	B-NP	HYPH	I-protein	31	NMOD	I-protein
T33	I-Entity	874	880	kappaB	kappaB	I-NP	NN	I-protein	32	NMOD	I-protein
O	O	881	891	activation	activation	I-NP	NN	O	38	NMOD	O
O	O	891	892	,	,	O	,	O	38	P	O
O	O	893	896	and	and	O	CC	O	38	NMOD	O
T15	B-Protein	897	904	IkappaB	IkappaB	B-NP	NN	B-protein	38	NMOD	B-protein
T15	I-Protein	904	905	-	-	O	HYPH	O	38	NMOD	O
T15	I-Protein	905	910	alpha	alpha	B-NP	SYM	O	38	NMOD	O
O	O	911	922	degradation	degradation	I-NP	NN	O	15	PMOD	O
O	O	922	923	.	.	O	.	O	6	P	O

O	O	924	933	Monocytes	Monocyte	B-NP	NNS	B-cell_type	2	SUB	B-cell_type
O	O	934	938	were	be	B-VP	VBD	O	0	ROOT	O
O	O	939	947	isolated	isolate	I-VP	VBN	O	2	VC	O
O	O	948	952	from	from	B-PP	IN	O	3	VMOD	O
O	O	953	958	human	human	B-NP	JJ	O	6	NMOD	O
O	O	959	965	donors	donor	I-NP	NNS	O	4	PMOD	O
O	O	965	966	.	.	O	.	O	2	P	O

O	O	967	972	Cells	Cell	B-NP	NNS	O	2	SUB	O
O	O	973	977	were	be	B-VP	VBD	O	0	ROOT	O
O	O	978	988	stimulated	stimulate	I-VP	VBN	O	2	VC	O
O	O	989	993	with	with	B-PP	IN	O	3	VMOD	O
O	O	994	1003	endotoxin	endotoxin	B-NP	NN	B-protein	4	PMOD	B-protein
O	O	1004	1005	(	(	O	(	O	13	DEP	O
O	O	1005	1008	LPS	LPS	B-NP	NN	O	12	NMOD	O
O	O	1008	1009	,	,	O	,	O	12	P	O
O	O	1010	1013	100	100	B-NP	CD	O	12	NMOD	O
O	O	1014	1016	ng	ng	I-NP	NN	O	12	NMOD	O
O	O	1016	1017	/	/	B-NP	SYM	O	12	NMOD	O
O	O	1017	1019	mL	mL	I-NP	NN	O	13	DEP	O
O	O	1019	1020	)	)	O	)	O	5	NMOD	O
O	O	1021	1025	with	with	B-PP	IN	O	5	NMOD	O
O	O	1026	1029	and	and	O	CC	O	14	PMOD	O
O	O	1030	1037	without	without	B-PP	IN	O	14	PMOD	O
O	O	1038	1043	human	human	B-NP	JJ	O	18	NMOD	O
T16	B-Protein	1044	1046	IL	IL	I-NP	NN	O	14	PMOD	O
T16	I-Protein	1046	1047	-	-	O	HYPH	O	26	P	O
T16	I-Protein	1047	1049	10	10	B-NP	CD	O	26	DEP	O
O	O	1050	1051	(	(	O	(	O	26	DEP	O
O	O	1051	1053	10	10	B-NP	CD	O	25	NMOD	O
O	O	1054	1056	ng	ng	I-NP	NN	O	25	NMOD	O
O	O	1056	1057	/	/	B-NP	SYM	O	25	NMOD	O
O	O	1057	1059	mL	mL	I-NP	NN	O	26	DEP	O
O	O	1059	1060	)	)	O	)	O	18	NMOD	O
O	O	1060	1061	.	.	O	.	O	2	P	O

O	O	1062	1071	Following	Follow	B-PP	VBG	O	7	VMOD	O
O	O	1072	1083	stimulation	stimulation	B-NP	NN	O	1	PMOD	O
O	O	1083	1084	,	,	O	,	O	7	P	O
T17	B-Protein	1085	1088	TNF	TNF	B-NP	NN	B-protein	6	NMOD	B-protein
T17	I-Protein	1088	1089	-	-	O	HYPH	O	6	P	O
T17	I-Protein	1089	1094	alpha	alpha	B-NP	SYM	O	7	SUB	O
O	O	1095	1098	was	be	B-VP	VBD	O	29	VMOD	O
O	O	1099	1107	measured	measure	I-VP	VBN	O	7	VC	O
O	O	1108	1110	in	in	B-PP	IN	O	8	VMOD	O
O	O	1111	1115	cell	cell	B-NP	NN	O	11	NMOD	O
O	O	1116	1128	supernatants	supernatant	I-NP	NNS	O	9	PMOD	O
O	O	1129	1131	by	by	B-PP	IN	O	8	VMOD	O
O	O	1132	1137	ELISA	ELISA	B-NP	NN	O	17	NMOD	O
O	O	1137	1138	,	,	O	,	O	17	P	O
T34	B-Entity	1139	1141	NF	NF	B-NP	NN	B-protein	17	NMOD	B-protein
T34	I-Entity	1141	1142	-	-	B-NP	HYPH	I-protein	17	NMOD	I-protein
T34	I-Entity	1142	1148	kappaB	kappaB	I-NP	NN	I-protein	18	NMOD	I-protein
O	O	1149	1157	activity	activity	I-NP	NN	O	12	PMOD	O
O	O	1158	1160	by	by	B-PP	IN	O	8	VMOD	O
O	O	1161	1176	electrophoretic	electrophoretic	B-NP	JJ	O	23	NMOD	O
O	O	1177	1185	mobility	mobility	I-NP	NN	O	23	NMOD	O
O	O	1186	1191	shift	shift	I-NP	NN	O	23	NMOD	O
O	O	1192	1197	assay	assay	I-NP	NN	O	19	PMOD	O
O	O	1197	1198	,	,	O	,	O	29	P	O
O	O	1199	1202	and	and	O	CC	O	29	NMOD	O
T18	B-Protein	1203	1210	IkappaB	IkappaB	B-NP	NN	B-protein	29	NMOD	B-protein
T18	I-Protein	1210	1211	-	-	O	HYPH	O	29	P	O
T18	I-Protein	1211	1216	alpha	alpha	O	SYM	O	29	NMOD	O
O	O	1217	1223	levels	level	B-NP	NNS	O	0	ROOT	O
O	O	1224	1226	by	by	B-PP	IN	O	29	NMOD	O
O	O	1227	1234	Western	Western	B-NP	JJ	O	32	NMOD	O
O	O	1235	1239	blot	blot	I-NP	NN	O	30	PMOD	O
O	O	1239	1240	.	.	O	.	O	29	P	O

O	O	1241	1243	We	We	B-NP	PRP	O	2	SUB	O
O	O	1244	1252	observed	observe	B-VP	VBD	O	0	ROOT	O
O	O	1253	1257	that	that	B-SBAR	IN	O	2	VMOD	O
O	O	1258	1263	after	after	B-SBAR	IN	O	3	DEP	O
O	O	1264	1267	LPS	LPS	B-NP	NN	O	6	NMOD	O
O	O	1268	1279	stimulation	stimulation	I-NP	NN	O	11	NMOD	O
O	O	1280	1282	of	of	B-PP	IN	O	6	NMOD	O
O	O	1283	1288	human	human	B-NP	JJ	B-cell_type	9	NMOD	B-cell_type
O	O	1289	1298	monocytes	monocyte	I-NP	NNS	I-cell_type	7	PMOD	I-cell_type
O	O	1298	1299	,	,	O	,	O	11	P	O
T19	B-Protein	1300	1303	TNF	TNF	B-NP	NN	B-protein	13	NMOD	B-protein
T19	I-Protein	1303	1304	-	-	B-PP	HYPH	O	13	P	O
T19	I-Protein	1304	1309	alpha	alpha	B-NP	SYM	O	4	PMOD	O
O	O	1310	1319	increased	increase	B-VP	VBN	O	13	NMOD	O
O	O	1320	1322	to	to	B-PP	TO	O	14	VMOD	O
O	O	1323	1326	798	798	B-NP	CD	O	23	NMOD	O
O	O	1326	1327	+	+	O	SYM	O	23	NMOD	O
O	O	1327	1328	/	/	O	SYM	O	23	P	O
O	O	1328	1329	-	-	O	SYM	O	23	NMOD	O
O	O	1329	1331	67	67	B-NP	CD	O	23	NMOD	O
O	O	1332	1334	pg	pg	I-NP	NN	O	23	NMOD	O
O	O	1334	1335	/	/	B-NP	SYM	O	23	NMOD	O
O	O	1335	1337	mL	mL	B-NP	NN	O	15	PMOD	O
O	O	1338	1339	(	(	O	(	O	31	DEP	O
O	O	1339	1340	p	p	B-NP	NN	O	30	NMOD	O
O	O	1341	1342	<	<	B-ADJP	SYM	O	25	NMOD	O
O	O	1343	1344	.	.	O	.	O	26	P	O
O	O	1344	1347	001	001	B-NP	CD	O	26	AMOD	O
O	O	1348	1354	versus	versus	O	CC	O	30	NMOD	O
O	O	1355	1362	control	control	B-NP	NN	O	31	DEP	O
O	O	1362	1363	)	)	O	)	O	13	NMOD	O
O	O	1363	1364	.	.	O	.	O	2	P	O

T20	B-Protein	1365	1367	IL	IL	B-NP	NN	B-protein	2	NMOD	B-protein
T20	I-Protein	1367	1368	-	-	B-NP	HYPH	I-protein	4	SUB	I-protein
T20	I-Protein	1368	1370	10	10	I-NP	CD	I-protein	2	NMOD	I-protein
O	O	1371	1381	attenuated	attenuate	B-VP	VBD	O	0	ROOT	O
O	O	1382	1385	LPS	LPS	B-NP	NN	O	11	NMOD	O
O	O	1385	1386	-	-	O	HYPH	O	5	P	O
O	O	1386	1396	stimulated	stimulate	B-NP	VBN	O	11	NMOD	O
T21	B-Protein	1397	1400	TNF	TNF	I-NP	NN	B-protein	11	NMOD	B-protein
T21	I-Protein	1400	1401	-	-	O	HYPH	O	11	NMOD	O
T21	I-Protein	1401	1406	alpha	alpha	O	SYM	O	11	NMOD	O
O	O	1407	1417	production	production	B-NP	NN	O	4	OBJ	O
O	O	1418	1419	(	(	O	(	O	20	DEP	O
O	O	1419	1422	297	297	B-NP	CD	O	20	NMOD	O
O	O	1422	1423	+	+	O	SYM	O	13	NMOD	O
O	O	1423	1424	/	/	O	SYM	O	14	AMOD	O
O	O	1424	1425	-	-	O	SYM	O	15	AMOD	O
O	O	1425	1427	54	54	B-NP	CD	O	16	AMOD	O
O	O	1427	1428	;	;	O	:	O	13	P	O
O	O	1429	1430	p	p	B-NP	NN	O	20	NMOD	O
O	O	1431	1432	<	<	B-NP	SYM	O	11	NMOD	O
O	O	1433	1434	.	.	O	.	O	4	P	O
O	O	1434	1437	001	001	B-NP	CD	O	24	NMOD	O
O	O	1438	1444	versus	versus	O	CC	O	24	NMOD	O
O	O	1445	1448	LPS	LPS	B-NP	NN	O	4	VMOD	O
O	O	1449	1454	alone	alone	B-ADVP	RB	O	24	NMOD	O
O	O	1454	1455	)	)	O	)	O	24	NMOD	O
O	O	1455	1456	.	.	O	.	O	4	P	O

O	O	1457	1462	After	After	B-PP	IN	O	21	VMOD	O
O	O	1463	1466	LPS	LPS	B-NP	NN	O	3	NMOD	O
O	O	1467	1478	stimulation	stimulation	I-NP	NN	O	1	PMOD	O
O	O	1479	1481	in	in	B-PP	IN	O	3	NMOD	O
O	O	1482	1487	human	human	B-NP	JJ	B-cell_type	6	NMOD	B-cell_type
O	O	1488	1497	monocytes	monocyte	I-NP	NNS	I-cell_type	4	PMOD	I-cell_type
O	O	1497	1498	,	,	O	,	O	21	P	O
T22	B-Protein	1499	1506	IkappaB	IkappaB	B-NP	NN	B-protein	12	NMOD	B-protein
T22	I-Protein	1506	1507	-	-	O	HYPH	O	12	NMOD	O
T22	I-Protein	1507	1512	alpha	alpha	B-NP	SYM	O	12	NMOD	O
O	O	1513	1520	protein	protein	I-NP	NN	O	12	NMOD	O
O	O	1521	1527	levels	level	I-NP	NNS	O	13	SUB	O
O	O	1528	1537	decreased	decrease	B-VP	VBD	O	21	VMOD	O
O	O	1537	1538	,	,	O	,	O	21	P	O
O	O	1539	1542	and	and	O	CC	O	21	VMOD	O
T35	B-Entity	1543	1545	NF	NF	B-NP	NN	B-protein	18	NMOD	B-protein
T35	I-Entity	1545	1546	-	-	I-NP	HYPH	I-protein	18	NMOD	I-protein
T35	I-Entity	1546	1552	kappaB	kappaB	I-NP	NN	I-protein	20	NMOD	I-protein
T36	I-Entity	1553	1556	DNA	DNA	I-NP	NN	O	20	NMOD	O
O	O	1557	1564	binding	binding	I-NP	NN	O	21	SUB	O
O	O	1565	1574	increased	increase	B-VP	VBD	O	0	ROOT	O
O	O	1574	1575	.	.	O	.	O	21	P	O

T23	B-Protein	1576	1578	IL	IL	B-NP	NN	B-protein	4	NMOD	B-protein
T23	I-Protein	1578	1579	-	-	I-NP	HYPH	I-protein	1	P	I-protein
T23	I-Protein	1579	1581	10	10	I-NP	CD	I-protein	1	NMOD	I-protein
O	O	1582	1594	pretreatment	pretreatment	I-NP	NN	O	5	SUB	O
O	O	1595	1604	prevented	prevent	B-VP	VBD	O	0	ROOT	O
O	O	1605	1608	LPS	LPS	B-NP	NN	O	9	NMOD	O
O	O	1608	1609	-	-	B-NP	HYPH	O	9	NMOD	O
O	O	1609	1616	induced	induce	I-NP	VBN	O	9	NMOD	O
O	O	1617	1626	decreases	decrease	I-NP	NNS	O	5	OBJ	O
O	O	1627	1629	in	in	B-PP	IN	O	9	NMOD	O
T24	B-Protein	1630	1637	IkappaB	IkappaB	B-NP	NN	B-protein	15	NMOD	B-protein
T24	I-Protein	1637	1638	-	-	O	HYPH	O	15	P	O
T24	I-Protein	1638	1643	alpha	alpha	B-NP	SYM	O	15	NMOD	O
O	O	1644	1651	protein	protein	I-NP	NN	O	15	NMOD	O
O	O	1652	1658	levels	level	I-NP	NNS	O	10	PMOD	O
O	O	1659	1662	and	and	O	CC	O	5	VMOD	O
O	O	1663	1673	attenuated	attenuate	B-VP	VBD	O	5	VMOD	O
T37	B-Entity	1674	1676	NF	NF	B-NP	NN	B-protein	20	NMOD	B-protein
T37	I-Entity	1676	1677	-	-	B-NP	HYPH	I-protein	20	NMOD	I-protein
T37	I-Entity	1677	1683	kappaB	kappaB	I-NP	NN	I-protein	22	NMOD	I-protein
T38	I-Entity	1684	1687	DNA	DNA	I-NP	NN	O	22	NMOD	O
O	O	1688	1695	binding	binding	I-NP	NN	O	17	OBJ	O
O	O	1695	1696	.	.	O	.	O	5	P	O

T25	B-Protein	1697	1699	IL	IL	B-NP	NN	B-protein	4	SUB	B-protein
T25	I-Protein	1699	1700	-	-	O	HYPH	I-protein	1	P	I-protein
T25	I-Protein	1700	1702	10	10	B-NP	CD	I-protein	1	NMOD	I-protein
O	O	1703	1710	appears	appear	B-VP	VBZ	O	0	ROOT	O
O	O	1711	1713	to	to	I-VP	TO	O	6	VMOD	O
O	O	1714	1721	prevent	prevent	I-VP	VB	O	4	VMOD	O
O	O	1722	1732	activation	activation	B-NP	NN	O	6	OBJ	O
O	O	1733	1735	of	of	B-PP	IN	O	7	NMOD	O
T39	B-Entity	1736	1738	NF	NF	B-NP	NN	B-protein	11	NMOD	B-protein
T39	I-Entity	1738	1739	-	-	B-NP	HYPH	I-protein	11	NMOD	I-protein
T39	I-Entity	1739	1745	kappaB	kappaB	I-NP	NN	I-protein	8	PMOD	I-protein
O	O	1746	1748	by	by	B-PP	IN	O	6	VMOD	O
O	O	1749	1759	preserving	preserve	B-VP	VBG	O	12	PMOD	O
T26	B-Protein	1760	1767	IkappaB	IkappaB	B-NP	NN	B-protein	18	NMOD	B-protein
T26	I-Protein	1767	1768	-	-	O	HYPH	O	18	P	O
T26	I-Protein	1768	1773	alpha	alpha	B-NP	SYM	O	18	NMOD	O
O	O	1774	1781	protein	protein	I-NP	NN	O	18	NMOD	O
O	O	1782	1788	levels	level	I-NP	NNS	O	13	OBJ	O
O	O	1788	1789	,	,	O	,	O	13	P	O
O	O	1790	1797	leading	lead	B-VP	VBG	O	13	VMOD	O
O	O	1798	1800	to	to	B-PP	TO	O	20	VMOD	O
O	O	1801	1802	a	a	B-NP	DT	O	23	NMOD	O
O	O	1803	1812	reduction	reduction	I-NP	NN	O	21	PMOD	O
O	O	1813	1815	in	in	B-PP	IN	O	23	NMOD	O
T27	B-Protein	1816	1819	TNF	TNF	B-NP	NN	B-protein	28	NMOD	B-protein
T27	I-Protein	1819	1820	-	-	O	HYPH	O	28	NMOD	O
T27	I-Protein	1820	1825	alpha	alpha	B-NP	SYM	O	28	NMOD	O
O	O	1826	1833	release	release	I-NP	NN	O	24	PMOD	O
O	O	1833	1834	.	.	O	.	O	4	P	O
